Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
29.06
+0.16 (0.55%)
Nov 21, 2024, 3:59 PM EST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
$655,321
Profits / Employee
$93,337
Market Cap
54.25B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Sandoz Group AG | 22,633 |
| Telix Pharmaceuticals Limited | 234 |
| Elekta AB (publ) | 4,718 |
| Ryman Healthcare Limited | 7,700 |
| Verano Holdings Corp. | 3,900 |
| Vireo Growth Inc. | 490 |
| Medexus Pharmaceuticals Inc. | 82 |
Daiichi Sankyo Company News
- 8 days ago - Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS - Business Wire
- 13 days ago - ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product - Benzinga
- 20 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well - CNBC
- 21 days ago - Daiichi Sankyo Company, Limited 2024 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 6 weeks ago - Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals - BNN Bloomberg
- 7 weeks ago - Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ... - GuruFocus
- 7 weeks ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy - Benzinga